<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04284995</url>
  </required_header>
  <id_info>
    <org_study_id>CEL-02</org_study_id>
    <nct_id>NCT04284995</nct_id>
  </id_info>
  <brief_title>A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction</brief_title>
  <acronym>CEL-02</acronym>
  <official_title>A Phase 2 Open Label Study to Assess the PK and PD Properties of a Single Subcutaneous Injection of RUC-4 in Patients With a ST-elevation Myocardial Infarction Presenting to the Cardiac Catheterization Lab With Planned Primary Coronary Angioplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CeleCor Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ST. Antonius hospital Nieuwegein</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diagram B.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CeleCor Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RUC-4 is a novel, promising and fast acting (5-15 minutes) αIIbβ3 receptor antagonist with a&#xD;
      high-grade inhibition of platelet aggregation (≥80%) shortly after subcutaneous&#xD;
      administration. This study is designed to extend the findings in CEL-01 to patients with&#xD;
      ST-elevation myocardial Infarction (STEMI) presenting to the cardiac catheterization&#xD;
      laboratory with planned coronary angioplasty.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RUC-4 is a novel, promising and fast acting (5-15 minutes) αIIbβ3 receptor antagonist with a&#xD;
      high-grade inhibition of platelet aggregation (≥80%) shortly after subcutaneous&#xD;
      administration. For patients with ST-elevation myocardial infarction (STEMI) early treatment&#xD;
      with RUC-4 could be beneficial by improving initial patency of the infarct related vessel and&#xD;
      by minimizing thrombotic occlusions, thus improving both coronary artery and myocardial&#xD;
      microvascular blood flow, possibly resulting in a decrease in infarct size and a reduction in&#xD;
      complications of STEMI.&#xD;
&#xD;
      The purpose of this study is to assess the PD and PK properties of a single subcutaneous&#xD;
      injection of RUC-4 in STEMI patients presenting to the cardiac catheterization laboratory&#xD;
      with planned coronary angioplasty. In addition the safety and tolerability will be assessed&#xD;
      at baseline and hospital discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Actual">December 14, 2020</completion_date>
  <primary_completion_date type="Actual">November 8, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Inhibition</measure>
    <time_frame>Baseline</time_frame>
    <description>Inhibition of Platelet Aggregation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet Inhibition</measure>
    <time_frame>15 minutes</time_frame>
    <description>Inhibition of Platelet aggregation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet inhibition</measure>
    <time_frame>45 minutes</time_frame>
    <description>Inhibition of Platelet aggregation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet inhibition</measure>
    <time_frame>60 minutes</time_frame>
    <description>Inhibition of Platelet aggregation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet inhibition</measure>
    <time_frame>90 minutes</time_frame>
    <description>Inhibition of Platelet aggregation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet inhibition</measure>
    <time_frame>120 minutes</time_frame>
    <description>Inhibition of Platelet aggregation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet inhibition</measure>
    <time_frame>180 minutes</time_frame>
    <description>Inhibition of Platelet aggregation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RUC-4 Concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>concentration in blood (ng/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RUC-4 Concentration</measure>
    <time_frame>15 minutes</time_frame>
    <description>concentration in blood (ng/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RUC-4 Concentration</measure>
    <time_frame>45 minutes</time_frame>
    <description>concentration in blood (ng/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RUC-4 Concentration</measure>
    <time_frame>90 minutes</time_frame>
    <description>concentration in blood (ng/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RUC-4 Concentration</measure>
    <time_frame>120 minutes</time_frame>
    <description>concentration in blood (ng/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RUC-4 Concentration</measure>
    <time_frame>180 minutes</time_frame>
    <description>concentration in blood (ng/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Baseline</time_frame>
    <description>Bleeding events, Injection site reactions,vital signs, ECG, laboratory results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Hospital discharge</time_frame>
    <description>Bleeding events, Injection site reactions,vital signs, ECG, laboratory results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RUC-4 Concentration</measure>
    <time_frame>240 minutes</time_frame>
    <description>concentration in blood (ng/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet aggregation</measure>
    <time_frame>240 minutes</time_frame>
    <description>Inhibition of platelet aggregation</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Heart Diseases</condition>
  <condition>Vascular Diseases</condition>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: 0.075 mg/kg RUC-4. 8 STEMI Patients will be enrolled.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: Dose of RUC-4 selected by Safety Review Committee (SRC) after completion of Cohort 2 and review of data. 8 STEMI Patients will be enrolled.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3: Dose of RUC-4 selected by Safety Review Committee (SRC) after completion of Cohort 2 and review of data. 8 STEMI Patients will be enrolled.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RUC-4 Compound</intervention_name>
    <description>All patients will receive a single subcutaneous dose of RUC-4 in the Cardiac Catheterization Lab (CCL) before coronary angiography/percutaneous coronary intervention.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with STEMI, presenting with persistent chest pain (&gt;30 min) and ≥1 mm&#xD;
             ST-segment elevation in two adjacent electrocardiograph leads, with &gt;6 mm cumulative&#xD;
             ST-segment deviation, in whom the total duration of symptoms to first intracoronary&#xD;
             device deployment (excluding a wire) is anticipated to be within 6 hours&#xD;
&#xD;
          2. Adult males and females 18 years of age or older&#xD;
&#xD;
          3. Females must be non-pregnant, non-lactating, and of non-childbearing potential&#xD;
             (postmenopausal or surgically sterilized) by history and review of medical record&#xD;
&#xD;
          4. Weight (by history) of between 52 and 120 kg&#xD;
&#xD;
          5. Written informed consent (following short-form of the informed consent form at Cardiac&#xD;
             Catheterization Lab)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. High probability in the opinion of the cardiologist that current STEMI is caused by&#xD;
             stent thrombosis and the previous PCI related to this stent thrombosis is &lt;1 month&#xD;
&#xD;
          2. High suspicion of type II MI&#xD;
&#xD;
          3. Out of hospital cardiac arrest (OHCA)&#xD;
&#xD;
          4. Therapy resistant cardiogenic shock (systolic blood pressure ≤80 mm Hg for &gt;30&#xD;
             minutes)&#xD;
&#xD;
          5. Persistent severe hypertension (systolic blood pressure &gt;180 mm Hg or diastolic blood&#xD;
             pressure &gt;110 mm Hg)&#xD;
&#xD;
          6. Current active coronavirus disease 2019 (COVID-19) infection (criteria according to&#xD;
             local guidelines)&#xD;
&#xD;
          7. Known severe liver disease&#xD;
&#xD;
          8. Known history of severe renal dysfunction (glomerular filtration rate &lt;30 mL/min or&#xD;
             serum creatinine &gt;200 mmol/L [&gt;2.5 mg/dL])&#xD;
&#xD;
          9. Known left bundle branch block&#xD;
&#xD;
         10. Requirement of oral anticoagulation (Vitamin K antagonists {VKA} or direct oral&#xD;
             antagonists {DOACs})&#xD;
&#xD;
         11. Current treatment with αIIbβ3 receptor antagonist (other than RUC-4)&#xD;
&#xD;
         12. Coagulation abnormality, known bleeding disorder, or history of documented prior&#xD;
             hemorrhagic or thrombotic stroke within the past 6 months&#xD;
&#xD;
         13. History of upper or lower GI bleeding within the past 6 months&#xD;
&#xD;
         14. Known clinically important anemia&#xD;
&#xD;
         15. Known clinically important thrombocytopenia (platelet count of less than 150,000/μL)&#xD;
&#xD;
         16. Known history of allergy to any of the ingredients in the RUC-4 formulation (i.e.,&#xD;
             acetate buffer, sucrose)&#xD;
&#xD;
         17. Major surgery within the past 6 months&#xD;
&#xD;
         18. Life expectancy of less than 6 months&#xD;
&#xD;
         19. Any clinically significant abnormality identified prior to enrollment that in the&#xD;
             judgment of the Investigator would preclude safe completion of the study&#xD;
&#xD;
         20. Unwillingness or inability to comply with the requirements of this protocol including&#xD;
             the presence of any condition (physical, mental, or social) that is likely to affect&#xD;
             the patient's ability to comply with the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Antonius hospital</name>
      <address>
        <city>Nieuwegein</city>
        <state>CM</state>
        <zip>3435</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 22, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

